Business Wire

Xylem’s New Smart Wastewater Treatment Solution Cuts Operating Costs and Reduces Energy Use by 25%

7.4.2022 15:00:00 EEST | Business Wire | Press release

Share

Wastewater utilities can now achieve compliance targets while cutting energy consumption from aeration by up to 25% with Xylem Edge Control. This off-the-shelf suite of digital solutions for conventional activated sludge (CAS) plants marks the latest breakthrough in the digitization of water utilities. With Xylem Edge Control, wastewater operators can now control and monitor their assets, improve nutrient removal, save energy and reduce costs.

“Wastewater utilities are constantly balancing the need to ensure service reliability and compliance alongside the need to manage costs,” said Chris Taylor, Global Product Manager at Xylem. “Xylem Edge Control helps wastewater utilities confidently walk that line, bringing together our digital innovation expertise and insights from our deep bioprocessing experience, in a suite of solutions that maximizes process control while dramatically cutting energy consumption and supporting sustainability goals.”

“Utilities around the world are well on the way to digitizing their networks and reaping major water, energy and cost efficiencies. Xylem Edge Control is a versatile, multi-functional solution that meets wastewater utilities where they are on that journey – and sets them up to unlock more of the benefits of digital transformation.”

The Edge Control solutions apply analytics to real-time data to provide rapid process recommendations to optimize chemical usage and aeration. As utilities target emissions reductions, Edge Control is the latest high-efficiency technology that can help utilities cut energy-related greenhouse gas (GHG) emissions and make fast progress towards achieving net-zero targets. The platform can operate with any Programmable Logic Controller under various communications protocols and connect to existing hardware, including sensors and probes.

Xylem Edge Control combines four solutions:

  1. Xylem Edge Control Pulsed Aeration: A digital, energy saving solution that can prevent over-aeration of underloaded treatment plants. Pulsed Aeration improves the overall biological process of CAS plants, to provide adequate mixing and ultimately achieving energy savings. Research and implementation of Pulsed Aeration has shown energy savings of approximately 25% can be achieved.
  2. Xylem Edge Control Ammonia Removal: Xylem Edge Control Ammonia Removal determines a CAS facility's ammonia target and helps meet its nutrient discharge limits while working to maximize energy savings. It uses an advanced algorithm to match various load conditions, that can provide consistent ammonia removal and further stabilize the biological process.
  3. Xylem Edge Control Ammonia + Nitrogen Removal: The solution offers wastewater utilities the potential to save energy while reducing nitrate and ammonia concentrations. It uses an advanced algorithm which communicates with CAS facilities’ existing assets to optimize the achievement of nutrient compliance targets. Its patented, one-of-a-kind, AvN® wastewater treatment process1 has the ability to create a biological environment unlike anything the wastewater treatment industry has seen with its capacity to create a Nitrite shunt. This can allow for an expedited denitrification process and ultimately, increased energy savings. Research and implementation of Ammonia + Nitrogen Removal has shown energy savings of approximately 25% in addition to a reduction in Total Inorganic Nitrogen (TIN) concentration of approximately 30%.
  4. Xylem Edge Control P - Removal: This solution controls chemical feed pumps based on real-time phosphorus concentrations to reduce chemical usage while meeting today’s stricter phosphorus limits.

The launch of Xylem Edge Control follows rigorous field testing across North America, including Washington and Indiana, including the wastewater treatment operations serving the city of Muncie, Indiana.

“With Muncie being the home to Ball State University, the city undergoes a major swing in population from around 70,000 people while school is in session to approximately 48,000 when school is out of session,” said Jason Ingram, Plant Superintendent at Muncie Wastewater Treatment Plant in Muncie, IN, where Xylem Edge Control Pulsed Aeration has been installed. “That’s a decrease in population of over 30%. It is during these months of decreased load where we benefit from Pulsed Aeration most. With our upgrades from Xylem’s Pulsed Aeration we are able to save $5,000 a month on energy costs.”

Global water utilities account for approximately 2% of global GHG emissions – the equivalent of the world’s shipping industry. However, innovative solutions like Edge Control can help mitigate a substantial portion of the emissions generated by inefficient wastewater operations, quickly and affordably. Furthermore, by deploying readily available advanced solutions, utilities could cut the water industry’s GHG emissions by 50% across both clean water and wastewater activities.

Xylem Edge Control can be used as a stand-alone process or as a connected, subscription-based enterprise with fees based on efficiency and savings. When connected via the Cloud, Xylem Edge Control provides data visualization, allowing the customer to see the energy savings on a monthly basis; real-time data trending reports, showing details such as ammonia and TIN concentrations and alert and alarm texts/email notifications, displaying instrumentation and software status.

Xylem Edge Control Pulsed Aeration, Xylem Edge Control Ammonia Removal and Xylem Edge Control Ammonia + Nitrogen Removal are now available for purchase globally. Xylem Edge Control P – Removal will be available to customers globally later this year.

About Xylem

Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.

________________________
1 AvN® is a trademark of World Water Works, Inc.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Houston Spencer
+1.914.240.3046
Houston.Spencer@xylem.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye